John R. Hess
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
John R. Hess has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
A.D. Knapp
From the Blood Research Detachment, Walter Reed Army Institute of Research, Washington, DC; and the Hoxworth Blood Center and the Saenger Radioisotope Laboratory, University of Cincinnati Medical Center, Cincinnati, Ohio
2 shared publicationsE.B. Silberstein
From the Blood Research Detachment, Walter Reed Army Institute of Research, Washington, DC; and the Hoxworth Blood Center and the Saenger Radioisotope Laboratory, University of Cincinnati Medical Center, Cincinnati, Ohio
2 shared publicationsJ.F. Gormas
From the Blood Research Detachment, Walter Reed Army Institute of Research, Washington, DC; and the Hoxworth Blood Center and the Saenger Radioisotope Laboratory, University of Cincinnati Medical Center, Cincinnati, Ohio
2 shared publicationsN. Rugg
From the Blood Research Detachment, Walter Reed Army Institute of Research, Washington, DC; and the Hoxworth Blood Center and the Saenger Radioisotope Laboratory, University of Cincinnati Medical Center, Cincinnati, Ohio
2 shared publicationsT.J. Greenwalt
From the Blood Research Detachment, Walter Reed Army Institute of Research, Washington, DC; and the Hoxworth Blood Center and the Saenger Radioisotope Laboratory, University of Cincinnati Medical Center, Cincinnati, Ohio
2 shared publications
Latest Publications
- 1 August 2000
- Published by Wiley in Transfusion
- Vol. 40 (8) , 1007-1011
Successful storage of RBCs for 9 weeks in a new additive solution
BACKGROUND: This study explored the effect of storing packed RBCs suspended in 200 mL of an alkaline, hypotonic, experimental additive solution (EAS 61).STUDY DESIGN AND METHODS: Packed RBC units prepared from RBCs collected from healthy donors in CPD were stored for 8 (n = 10) and 9 (n = 10) weeks under blood bank conditions after the addition of 200 mL of EAS 61 (adenine, 2 mM; dextrose, 110 mM; mannitol, 55 mM; NaCl, 26 mM; Na2HPO4, 12 mM). Standard methods were used for in vitro assays. The 24‐hour in vivo autologous recoveries were measured with 51Cr.RESULTS: Mean ± SD recoveries at 8 and 9 weeks were 81 ± 7 and 77 ± 7 percent. After 9 weeks, the ATP of the RBCs was 81 percent of the initial value, hemolysis was 0.35 percent, supernatant potassium was 46 mEq per L, and the morphologic index was 94.1.CONCLUSION: Packed RBCs suspended in 200 mL of EAS 61 can be stored satisfactorily for 9 weeks. Longer RBC storage should reduce outdating, increase availability of transfusions in remote locations, and improve the efficiency of autologous donor programs.
- 1 August 2000
- Published by Wiley in Transfusion
- Vol. 40 (8) , 1007-1011
Successful storage of RBCs for 9 weeks in a new additive solution
BACKGROUND: This study explored the effect of storing packed RBCs suspended in 200 mL of an alkaline, hypotonic, experimental additive solution (EAS 61).STUDY DESIGN AND METHODS: Packed RBC units prepared from RBCs collected from healthy donors in CPD were stored for 8 (n = 10) and 9 (n = 10) weeks under blood bank conditions after the addition of 200 mL of EAS 61 (adenine, 2 mM; dextrose, 110 mM; mannitol, 55 mM; NaCl, 26 mM; Na2HPO4, 12 mM). Standard methods were used for in vitro assays. The 24‐hour in vivo autologous recoveries were measured with 51Cr.RESULTS: Mean ± SD recoveries at 8 and 9 weeks were 81 ± 7 and 77 ± 7 percent. After 9 weeks, the ATP of the RBCs was 81 percent of the initial value, hemolysis was 0.35 percent, supernatant potassium was 46 mEq per L, and the morphologic index was 94.1.CONCLUSION: Packed RBCs suspended in 200 mL of EAS 61 can be stored satisfactorily for 9 weeks. Longer RBC storage should reduce outdating, increase availability of transfusions in remote locations, and improve the efficiency of autologous donor programs.
- 1 August 2000
- Published by Wiley in Transfusion
- Vol. 40 (8) , 1012-1016
Successful storage of RBCs for 10 weeks in a new additive solution
BACKGROUND: The effect of storing packed RBCs suspended in 300 mL of an alkaline, experimental additive solution (EAS 64) was explored.STUDY DESIGN AND METHODS: RBC units prepared from blood collected from healthy donors into CPD were WBC reduced and stored for 10 weeks under blood bank conditions after the addition of 300 mL of EAS 64 (adenine, 2 mM; dextrose, 50 mM; mannitol, 20 mM; NaCl, 75 mM; Na2HPO4, 9 mM). For comparison, non‐WBC‐reduced units from the same donors were stored in a different additive solution (AS‐1, Baxter Healthcare) for 6 weeks. Standard methods were used for the in vitro assays. The 24‐hour in vivo recoveries were measured by using 51Cr‐ and 99mTc‐labeled RBCs.RESULTS: Mean recovery in the EAS 64 units after 10 weeks was 84 ± 8 percent, the same as in the AS‐1 units stored for 6 weeks. For EAS 64 and AS‐1 units, respectively, the ATP of the RBCs was 85 percent and 64 percent of the initial value, hemolysis was 0.43 percent and 0.63 percent, supernatant potassium was 24 mEq per L and 44 mEq per L, and the morphologic index was 98 and 71.CONCLUSION: RBCs suspended in 300 mL of EAS 64 can be stored satisfactorily for 10 weeks. Longer RBC storage should reduce outdating, increase availability of transfusions in remote locations, and improve the efficiency of autologous donor programs.
- 1 August 2000
- Published by Wiley in Transfusion
- Vol. 40 (8) , 1012-1016
Successful storage of RBCs for 10 weeks in a new additive solution
BACKGROUND: The effect of storing packed RBCs suspended in 300 mL of an alkaline, experimental additive solution (EAS 64) was explored.STUDY DESIGN AND METHODS: RBC units prepared from blood collected from healthy donors into CPD were WBC reduced and stored for 10 weeks under blood bank conditions after the addition of 300 mL of EAS 64 (adenine, 2 mM; dextrose, 50 mM; mannitol, 20 mM; NaCl, 75 mM; Na2HPO4, 9 mM). For comparison, non‐WBC‐reduced units from the same donors were stored in a different additive solution (AS‐1, Baxter Healthcare) for 6 weeks. Standard methods were used for the in vitro assays. The 24‐hour in vivo recoveries were measured by using 51Cr‐ and 99mTc‐labeled RBCs.RESULTS: Mean recovery in the EAS 64 units after 10 weeks was 84 ± 8 percent, the same as in the AS‐1 units stored for 6 weeks. For EAS 64 and AS‐1 units, respectively, the ATP of the RBCs was 85 percent and 64 percent of the initial value, hemolysis was 0.43 percent and 0.63 percent, supernatant potassium was 24 mEq per L and 44 mEq per L, and the morphologic index was 98 and 71.CONCLUSION: RBCs suspended in 300 mL of EAS 64 can be stored satisfactorily for 10 weeks. Longer RBC storage should reduce outdating, increase availability of transfusions in remote locations, and improve the efficiency of autologous donor programs.
- 1 January 1999
- Published by Springer Nature in BioDrugs
- Vol. 12 (2) , 81-90
Blood Substitutes for Surgery and Trauma
Solutions of modified haemoglobin and perfluorocarbon emulsions are currently being tested in advanced human trials. Concerns about renal injury and hypertension with the haemoglobin solutions, and drug retention and pulmonary injury with the perfluorocarbons have been successfully addressed. However, newly recognised inflammatory toxicities of the haemoglobin solutions and the low oxygen-carrying capacity of the perfluorocarbons remain as potential limits on efficacy. As a result, the role of blood substitutes will be less than originally imagined, and none is likely to be licenced for use for several years.
- 1 January 1999
- Published by Springer Nature in BioDrugs
- Vol. 12 (2) , 81-90
Blood Substitutes for Surgery and Trauma
Solutions of modified haemoglobin and perfluorocarbon emulsions are currently being tested in advanced human trials. Concerns about renal injury and hypertension with the haemoglobin solutions, and drug retention and pulmonary injury with the perfluorocarbons have been successfully addressed. However, newly recognised inflammatory toxicities of the haemoglobin solutions and the low oxygen-carrying capacity of the perfluorocarbons remain as potential limits on efficacy. As a result, the role of blood substitutes will be less than originally imagined, and none is likely to be licenced for use for several years.